Pathogenesis of common glomerular diseases - Role of the podocyte cytoskeleton

Cell Health and Cytoskeleton

Volumn 4, Issue , 2012, Pages 103-118

  Kumagai, Takanori ^a   Mouawad, Flaviana ^a   Takano, Tomoko ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Cytoskeleton; Glomerular disease; Podocyte; Proteinuria

Indexed keywords

ALPHA ACTININ 4; ANGIOPOIETIN; BETA3 INTEGRIN; CD2 ASSOCIATED PROTEIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; INTERLEUKIN 13; LAMININ; MYOSIN I; MYOSIN IE; NEF PROTEIN; NEPHRIN; PHOSPHOLIPASE C; PODOCIN; RAC1 PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ACTIN FILAMENT; CELL FUNCTION; CYTOSKELETON; DIABETIC NEPHROPATHY; EDEMA; ENDOCYTOSIS; FOCAL GLOMERULOSCLEROSIS; GLOMERULOPATHY; HIV ASSOCIATED NEPHROPATHY; HUMAN; MEMBRANOUS GLOMERULONEPHRITIS; MESANGIUM CELL; MINIMAL CHANGE GLOMERULONEPHRITIS; MOLECULAR INTERACTION; NEPHROSCLEROSIS; NONHUMAN; PATHOGENESIS; PODOCYTE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEINURIA; REVIEW; SIGNAL TRANSDUCTION; TH2 CELL;

EID: 84874784722     PISSN: None     EISSN: 11791330     Source Type: Journal    
DOI: 10.2147/CHC.S35534     Document Type: Review

References (175)

1. Mundel P, Kriz W. Structure and function of podocytes: an update. Anat Embryol (Berl). 1995;192(5):385-397.
2. Faul C, Asanuma K, Yanagida-Asanuma E, Kim K, Mundel P. Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton. Trends Cell Biol. 2007;17(9):428-437.
3. Jefferson JA, Alpers CE, Shankland SJ. Podocyte biology for the bedside. Am J Kidney Dis. 2011;58(5):835-845.
4. Asanuma K, Mundel P. The role of podocytes in glomerular pathobiology. Clin Exp Nephrol. 2003;7(4):255-259.
5. Greka A, Mundel P. Cell biology and pathology of podocytes. Annu Rev Physiol. 2012;74:299-323.
6. Saxen L, Sariola H. Early organogenesis of the kidney. Pediatr Nephrol. 1987;1(3):385-392.
7. Welsh GI, Saleem MA. The podocyte cytoskeleton-key to a functioning glomerulus in health and disease. Nat Rev Nephrol. 2012;8(1):14-21.
8. Saleem MA, Zavadil J, Bailly M, etal. The molecular and functional phenotype of glomerular podocytes reveals key features of contractile smooth muscle cells. Am J Physiol Renal Physiol. 2008;295(4):F959-F970.
9. Reiser J, Kriz W, Kretzler M, Mundel P. The glomerular slit diaphragm is a modified adherens junction. J Am Soc Nephrol. 2000;11(1):1-8.
10. Endlich N, Endlich K. Stretch, tension and adhesion-adaptive mechanisms of the actin cytoskeleton in podocytes. Eur J Cell Biol. 2006;85(3-4):229-234.
11. Friedrich C, Endlich N, Kriz W, Endlich K. Podocytes are sensitive to fluid shear stress in vitro. Am J Physiol Renal Physiol. 2006;291(4):F856-F865.
12. Endlich N, Kress KR, Reiser J, etal. Podocytes respond to mechanical stress in vitro. J Am Soc Nephrol. 2001;12(3):413-422.
13. Neal CR, Muston PR, Njegovan D, etal. Glomerular filtration into the subpodocyte space is highly restricted under physiological perfusion conditions. Am J Physiol Renal Physiol. 2007;293(6):F1787-F1798.
14. Salmon AH, Toma I, Sipos A, etal. Evidence for restriction of fluid and solute movement across the glomerular capillary wall by the subpodocyte space. Am J Physiol Renal Physiol. 2007;293(6):F1777-F1786.
15. Peti-Peterdi J, Sipos A. A high-powered view of the filtration barrier. J Am Soc Nephrol. 2010;21(11):1835-1841.
16. Lewis EJ, Schwartz MM, Pauli BU, Sharon Z. Endocytosis: a property of the glomerular visceral epithelial cell. Nephron. 1978;22(1-3):91-96.
17. Eyre J, Ioannou K, Grubb BD, etal. Statin-sensitive endocytosis of albumin by glomerular podocytes. Am J Physiol Renal Physiol. 2007;292(2):F674-F681.
18. Akilesh S, Huber TB, Wu H, etal. Podocytes use FcRn to clear IgG from the glomerular basement membrane. Proc Natl Acad Sci USA. 2008;105(3):967-972.
19. Abrahamson DR, Hudson BG, Stroganova L, Borza DB, St John PL. Cellular origins of type IV collagen networks in developing glomeruli. J Am Soc Nephrol. 2009;20(7):1471-1479.
20. Miner JH. Developmental biology of glomerular basement membrane components. Curr Opin Nephrol Hypertens. 1998;7(1):13-19.
21. St John PL, Abrahamson DR. Glomerular endothelial cells and podocytes jointly synthesize laminin-1 and-11 chains. Kidney Int. 2001;60(3):1037-1046.
22. Schlondorff D, Banas B. The mesangial cell revisited: no cell is an island. J Am Soc Nephrol. 2009;20(6):1179-1187.
23. Eremina V, Cui S, Gerber H, etal. Vascular endothelial growth factor A signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. J Am Soc Nephrol. 2006;17(3):724-735.
24. Banas B, Wornle M, Berger T, etal. Roles of SLC/CCL21 and CCR7in human kidney for mesangial proliferation, migration, apoptosis, and tissue homeostasis. J Immunol. 2002;168(9):4301-4307.
25. Ding M, Cui S, Li C, etal. Loss of the tumor suppressor Vhlh leads to upregulation of Cxcr4 and rapidly progressive glomerulonephritis in mice. Nat Med. 2006;12(9):1081-1087.
26. Banas MC, Banas B, Hudkins KL, etal. TLR4 links podocytes with the innate immune system to mediate glomerular injury. J Am Soc Nephrol. 2008;19(4):704-713.
27. Reiser J, von Gersdorff G, Loos M, etal. Induction of B7-1in podocytes is associated with nephrotic syndrome. J Clin Invest. 2004;113(10):1390-1397.
28. [No authors listed]. Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int. 1978;13(2):159-165.
29. Ali AA, Wilson E, Moorhead JF, etal. Minimal-change glomerular nephritis. Normal kidneys in an abnormal environment? Transplantation. 1994;58(7):849-852.
30. Shalhoub RJ. Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet. 1974;2(7880):556-560.
31. Koyama A, Fujisaki M, Kobayashi M, Igarashi M, Narita M. A glomerular permeability factor produced by human T cell hybridomas. Kidney Int. 1991;40(3):453-460.
32. Chugh SS, Clement LC, Mace C. New insights into human minimal change disease: lessons from animal models. Am J Kidney Dis. 2012;59(2):284-292.
33. Yap HK, Cheung W, Murugasu B, Sim SK, Seah CC, Jordan SC. Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: evidence for increased IL-13mRNA expression in relapse. J Am Soc Nephrol. 1999;10(3):529-537.
34. Lai KW, Wei CL, Tan LK, etal. Overexpression of interleukin-13induces minimal-change-like nephropathy in rats. J Am Soc Nephrol. 2007;18(5):1476-1485.
35. Clement LC, Avila-Casado C, Mace C, etal. Podocyte-secreted angiopoietin-like-4mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nat Med. 2011;17(1):117-122.
36. Garin EH, Mu W, Arthur JM, etal. Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis. Kidney Int. 2010;78(3):296-302.
37. Reiser J, Mundel P. Danger signaling by glomerular podocytes defines a novel function of inducible B7-1in the pathogenesis of nephrotic syndrome. J Am Soc Nephrol. 2004;15(9):2246-2248.
38. Kitiyakara C, Kopp JB, Eggers P. Trends in the epidemiology of focal segmental glomerulosclerosis. Semin Nephrol. 2003;23(2):172-182.
39. D'Agati VD, Kaskel FJ, Falk RJ. Focal segmental glomerulosclerosis. N Engl J Med. 2011;365(25):2398-2411.
40. Savin VJ, Sharma R, Sharma M, etal. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med. 1996;334(14):878-883.
41. Machuca E, Benoit G, Antignac C. Genetics of nephrotic syndrome: connecting molecular genetics to podocyte physiology. Hum Mol Genet. 2009;18(R2):R185-R194.
42. Klotman PE. HIV-associated nephropathy. Kidney Int. 1999;56(3):1161-1176.
43. Dubrow A, Mittman N, Ghali V, Flamenbaum W. The changing spectrum of heroin-associated nephropathy. Am J Kidney Dis. 1985;5(1):36-41.
44. Coroneos E, Petrusevska G, Varghese F, Truong LD. Focal segmental glomerulosclerosis with acute renal failure associated with alpha-interferon therapy. Am J Kidney Dis. 1996;28(6):888-892.
45. Kasiske BL, Crosson JT. Renal disease in patients with massive obesity. Arch Intern Med. 1986;146(6):1105-1109.
46. Rennke HG, Klein PS. Pathogenesis and significance of nonprimary focal and segmental glomerulosclerosis. Am J Kidney Dis. 1989;13(6):443-456.
47. Pollak MR. Focal segmental glomerulosclerosis: recent advances. Curr Opin Nephrol Hypertens. 2008;17(2):138-142.
48. McCarthy ET, Sharma M, Savin VJ. Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2010;5(11):2115-2121.
49. Wei C, El Hindi S, Li J, etal. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med. 2011;17(8):952-960.
50. Savin VJ, McCarthy ET, Sharma R, Charba D, Sharma M. Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity. Transl Res. 2008;151(6):288-292.
51. Shankland SJ, Pollak MR. A suPAR circulating factor causes kidney disease. Nat Med. 2011;17(8):926-927.
52. Borza CM, Su Y, Chen X, etal. Inhibition of integrin alpha2beta1 ameliorates glomerular injury. J Am Soc Nephrol. 2012;23(6):1027-1038.
53. Smith HW, Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol. 2010;11(1):23-36.
54. Maas RJ, Wetzels JF, Deegens JK. Serum-soluble urokinase receptor concentration in primary FSGS. Kidney Int. 2012;81(10):1043-1044.
55. Trachtman H, Gipson DS, Kaskel F, etal. Regarding Maas's editorial letter on serum suPAR levels. Kidney Int. 2012;82(4):492.
56. Kestila M, Lenkkeri U, Mannikko M, etal. Positionally cloned gene for a novel glomerular protein-nephrin-is mutated in congenital nephrotic syndrome. Mol Cell. 1998;1(4):575-582.
57. Philippe A, Nevo F, Esquivel EL, etal. Nephrin mutations can cause childhood-onset steroid-resistant nephrotic syndrome. J Am Soc Nephrol. 2008;19(10):1871-1878.
58. Santin S, Garcia-Maset R, Ruiz P, etal. Nephrin mutations cause childhood-and adult-onset focal segmental glomerulosclerosis. Kidney Int. 2009;76(12):1268-1276.
59. Huber TB, Benzing T. The slit diaphragm: a signaling platform to regulate podocyte function. Curr Opin Nephrol Hypertens. 2005;14(3):211-216.
60. Jones N, Blasutig IM, Eremina V, etal. Nck adaptor proteins link nephrin to the actin cytoskeleton of kidney podocytes. Nature. 2006;440(7085):818-823.
61. Verma R, Kovari I, Soofi A, Nihalani D, Patrie K, Holzman LB. Nephrin ectodomain engagement results in Src kinase activation, nephrin phosphorylation, Nck recruitment, and actin polymerization. J Clin Invest. 2006;116(5):1346-1359.
62. Li H, Zhu J, Aoudjit L, etal. Rat nephrin modulates cell morphology via the adaptor protein Nck. Biochem Biophys Res Commun. 2006;349(1):310-316.
63. Zhu J, Sun N, Aoudjit L, etal. Nephrin mediates actin reorganization via phosphoinositide 3-kinase in podocytes. Kidney Int. 2008;73(5):556-566.
64. George B, Verma R, Soofi AA, etal. Crk1/2-dependent signaling is necessary for podocyte foot process spreading in mouse models of glomerular disease. J Clin Invest. 2012;122(2):674-692.
65. Lehtonen S, Ryan JJ, Kudlicka K, Iino N, Zhou H, Farquhar MG. Cell junction-associated proteins IQGAP1, MAGI-2, CASK, spectrins, and alpha-actinin are components of the nephrin multiprotein complex. Proc Natl Acad Sci U S A. 2005;102(28):9814-9819.
66. Hirabayashi S, Mori H, Kansaku A, etal. MAGI-1 is a component of the glomerular slit diaphragm that is tightly associated with nephrin. Lab Invest. 2005;85(12):1528-1543.
67. Patrie KM, Drescher AJ, Welihinda A, Mundel P, Margolis B. Interaction of two actin-binding proteins, synaptopodin and alpha-actinin-4, with the tight junction protein MAGI-1. J Biol Chem. 2002;277(33):30183-30190.
68. Schwarz K, Simons M, Reiser J, etal. Podocin, a raft-associated component of the glomerular slit diaphragm, interacts with CD2AP and nephrin. J Clin Invest. 2001;108(11):1621-1629.
69. Goodman MB, Ernstrom GG, Chelur DS, O'Hagan R, Yao CA, Chalfie M. MEC-2 regulates C. elegans DEG/ENaC channels needed for mechanosensation. Nature. 2002;415(6875):1039-1042.
70. Huber TB, Schermer B, Muller RU, etal. Podocin and MEC-2 bind cholesterol to regulate the activity of associated ion channels. Proc Natl Acad Sci U S A. 2006;103(46):17079-17086.
71. Spassova MA, Hewavitharana T, Xu W, Soboloff J, Gill DL. A common mechanism underlies stretch activation and receptor activation of TRPC6 channels. Proc Natl Acad Sci U S A. 2006;103(44):16586-16591.
72. Huber TB, Schermer B, Benzing T. Podocin organizes ion channel-lipid supercomplexes: implications for mechanosensation at the slit diaphragm. Nephron Exp Nephrol. 2007;106(2):e27-e31.
73. Moller CC, Flesche J, Reiser J. Sensitizing the slit diaphragm with TRPC6 ion channels. J Am Soc Nephrol. 2009;20(5):950-953.
74. Roselli S, Heidet L, Sich M, etal. Early glomerular filtration defect and severe renal disease in podocin-deficient mice. Mol Cell Biol. 2004;24(2):550-560.
75. Boute N, Gribouval O, Roselli S, etal. NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet. 2000;24(4):349-354.
76. Tsukaguchi H, Sudhakar A, Le TC, etal. NPHS2mutations in late-onset focal segmental glomerulosclerosis: R229Q is a common disease-associated allele. J Clin Invest. 2002;110(11):1659-1666.
77. He N, Zahirieh A, Mei Y, etal. Recessive NPHS2 (Podocin) mutations are rare in adult-onset idiopathic focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2007;2(1):31-37.
78. Shih NY, Li J, Karpitskii V, etal. Congenital nephrotic syndrome in mice lacking CD2-associated protein. Science. 1999;286(5438):312-315.
79. Huber TB, Kwoh C, Wu H, etal. Bigenic mouse models of focal segmental glomerulosclerosis involving pairwise interaction of CD2AP, Fyn, and synaptopodin. J Clin Invest. 2006;116(5):1337-1345.
80. Kim JM, Wu H, Green G, etal. CD2-associated protein haploinsufficiency is linked to glomerular disease susceptibility. Science. 2003;300(5623):1298-1300.
81. Lowik MM, Groenen PJ, Pronk I, etal. Focal segmental glomerulosclerosis in a patient homozygous for a CD2AP mutation. Kidney Int. 2007;72(10):1198-1203.
82. Gigante M, Pontrelli P, Montemurno E, etal. CD2AP mutations are associated with sporadic nephrotic syndrome and focal segmental glomerulosclerosis (FSGS). Nephrol Dial Transplant. 2009;24(6):1858-1864.
83. Yaddanapudi S, Altintas MM, Kistler AD, etal. CD2AP in mouse and human podocytes controls a proteolytic program that regulates cytoskeletal structure and cellular survival. J Clin Invest. 2011;121(10):3965-3980.
84. Nijenhuis T, Sloan AJ, Hoenderop JG, etal. Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway. Am J Pathol. 2011;179(4):1719-1732.
85. Kos CH, Le TC, Sinha S, etal. Mice deficient in alpha-actinin-4 have severe glomerular disease. J Clin Invest. 2003;111(11):1683-1690.
86. Otey CA, Pavalko FM, Burridge K. An interaction between alpha-actinin and the beta 1integrin subunit in vitro. J Cell Biol. 1990;111(2):721-729.
87. Kaplan JM, Kim SH, North KN, etal. Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet. 2000;24(3):251-256.
88. Weins A, Kenlan P, Herbert S, etal. Mutational and biological analysis of alpha-actinin-4in focal segmental glomerulosclerosis. J Am Soc Nephrol. 2005;16(12):3694-3701.
89. Weins A, Schlondorff JS, Nakamura F, etal. Disease-associated mutant alpha-actinin-4reveals a mechanism for regulating its F-actin-binding affinity. Proc Natl Acad Sci U S A. 2007;104(41):16080-16085.
90. Meyrier A. Mechanisms of disease: focal segmental glomerulosclerosis. Nat Clin Pract Nephrol. 2005;1(1):44-54.
91. Aucella F, De Bonis P, Gatta G, etal. Molecular analysis of NPHS2 and ACTN4genes in a series of 33 Italian patients affected by adult-onset nonfamilial focal segmental glomerulosclerosis. Nephron Clin Pract. 2005;99(2):c31-c36.
92. Dai S, Wang Z, Pan X, etal. Functional analysis of promoter mutations in the ACTN4 and SYNPO genes in focal segmental glomerulosclerosis. Nephrol Dial Transplant. 2010;25(3):824-835.
93. Reiser J, Polu KR, Moller CC, etal. TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function. Nat Genet. 2005;37(7):739-744.
94. Kerjaschki D. Polycation-induced dislocation of slit diaphragms and formation of cell junctions in rat kidney glomeruli: the effects of low temperature, divalent cations, colchicine, and cytochalasin B. Lab Invest. 1978;39(5):430-440.
95. Prakash S, Chung KW, Sinha S, etal. Autosomal dominant progressive nephropathy with deafness: linkage to a new locus on chromosome 11q24. J Am Soc Nephrol. 2003;14(7):1794-1803.
96. Santin S, Ars E, Rossetti S, etal. TRPC6mutational analysis in a large cohort of patients with focal segmental glomerulosclerosis. Nephrol Dial Transplant. 2009;24(10):3089-3096.
97. Winn MP, Conlon PJ, Lynn KL, etal. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science. 2005;308(5729):1801-1804.
98. Tian D, Jacobo SM, Billing D, etal. Antagonistic regulation of actin dynamics and cell motility by TRPC5 and TRPC6 channels. Sci Signal. 2010;3(145):ra77.
99. Zhu L, Jiang R, Aoudjit L, Jones N, Takano T. Activation of RhoA in podocytes induces focal segmental glomerulosclerosis. J Am Soc Nephrol. 2011;22(9):1621-1630.
100. Wang L, Ellis MJ, Gomez JA, etal. Mechanisms of the proteinuria induced by Rho GTPases. Kidney Int. 2012;81(11):1075-1085.
101. Wing MR, Bourdon DM, Harden TK. PLC-epsilon: a shared effector protein in Ras-, Rho-, and G alpha beta gamma-mediated signaling. Mol Interv. 2003;3(5):273-280.
102. Freichel M, Vennekens R, Olausson J, etal. Functional role of TRPC proteins in native systems: implications from knockout and knock-down studies. J Physiol. 2005;567(Pt 1):59-66.
103. Hinkes B, Wiggins RC, Gbadegesin R, etal. Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible. Nat Genet. 2006;38(12):1397-1405.
104. Gbadegesin R, Hinkes BG, Hoskins BE, etal. Mutations in PLCE1 are a major cause of isolated diffuse mesangial sclerosis (IDMS). Nephrol Dial Transplant. 2008;23(4):1291-1297.
105. Boyer O, Benoit G, Gribouval O, etal. Mutational analysis of the PLCE1 gene in steroid resistant nephrotic syndrome. J Med Genet. 2010;47(7):445-452.
106. Brown EJ, Schlondorff JS, Becker DJ, etal. Mutations in the formin gene INF2 cause focal segmental glomerulosclerosis. Nat Genet. 2010;42(1):72-76.
107. Boyer O, Benoit G, Gribouval O, etal. Mutations in INF2 are a major cause of autosomal dominant focal segmental glomerulosclerosis. J Am Soc Nephrol. 2011;22(2):239-245.
108. Sun H, Schlondorff JS, Brown EJ, Higgs HN, Pollak MR. Rho activation of mDia formins is modulated by an interaction with inverted formin 2 (INF2). Proc Natl Acad Sci U S A. 2011;108(7):2933-2938.
109. Foth BJ, Goedecke MC, Soldati D. New insights into myosin evolution and classification. Proc Natl Acad Sci U S A. 2006;103(10):3681-3686.
110. Krendel M, Mooseker MS. Myosins: tails (and heads) of functional diversity. Physiology (Bethesda). 2005;20:239-251.
111. Krendel M, Kim SV, Willinger T, etal. Disruption of Myosin 1e promotes podocyte injury. J Am Soc Nephrol. 2009;20(1):86-94.
112. Sever S, Altintas MM, Nankoe SR, etal. Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease. J Clin Invest. 2007;117(8):2095-2104.
113. Mele C, Iatropoulos P, Donadelli R, etal. MYO1E mutations and childhood familial focal segmental glomerulosclerosis. N Engl J Med. 2011;365(4):295-306.
114. Hall A. Rho GTPases and the actin cytoskeleton. Science. 1998;279(5350):509-514.
115. Schmidt A, Hall A. Guanine nucleotide exchange factors for Rho GTPases: turning on the switch. Genes Dev. 2002;16(13):1587-1609.
116. Akilesh S, Suleiman H, Yu H, etal. Arhgap24inactivates Rac1in mouse podocytes, and a mutant form is associated with familial focal segmental glomerulosclerosis. J Clin Invest. 2011;121(10):4127-4137.
117. Ross MJ, Klotman PE. Recent progress in HIV-associated nephropathy. J Am Soc Nephrol. 2002;13(12):2997-3004.
118. Izzedine H, Deray G. The nephrologist in the HAART era. AIDS. 2007;21(4):409-421.
119. Bruggeman LA, Ross MD, Tanji N, etal. Renal epithelium is a previously unrecognized site of HIV-1 infection. J Am Soc Nephrol. 2000;11(11):2079-2087.
120. Sunamoto M, Husain M, He JC, Schwartz EJ, Klotman PE. Critical role for Nef in HIV-1-induced podocyte dedifferentiation. Kidney Int. 2003;64(5):1695-1701.
121. Zuo Y, Matsusaka T, Zhong J, etal. HIV-1genes vpr and nef synergistically damage podocytes, leading to glomerulosclerosis. J Am Soc Nephrol. 2006;17(10):2832-2843.
122. Lu TC, He JC, Wang ZH, etal. HIV-1Nef disrupts the podocyte actin cytoskeleton by interacting with diaphanous interacting protein. J Biol Chem. 2008;283(13):8173-8182.
123. Burridge K, Wennerberg K. Rho and Rac take center stage. Cell. 2004;116(2):167-179.
124. Mundel P, Reiser J. Proteinuria: an enzymatic disease of the podocyte? Kidney Int. 2010;77(7):571-580.
125. Shibata S, Nagase M, Yoshida S, etal. Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med. 2008;14(12):1370-1376.
126. Haas M, Meehan SM, Karrison TG, Spargo BH. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis. 1997;30(5):621-631.
127. Braden GL, Mulhern JG, O'Shea MH, Nash SV, Ucci AA Jr, Germain MJ. Changing incidence of glomerular diseases in adults. Am J Kidney Dis. 2000;35(5):878-883.
128. Rivera F, Lopez-Gomez JM, Perez-Garcia R. Clinicopathologic correlations of renal pathology in Spain. Kidney Int. 2004;66(3):898-904.
129. Cybulsky AV, Quigg RJ, Salant DJ. Experimental membranous nephropathy redux. Am J Physiol Renal Physiol. 2005;289(4):F660-F671.
130. Cybulsky AV. Membranous nephropathy. Contrib Nephrol. 2011;169:107-125.
131. Jefferson JA, Nelson PJ, Najafian B, Shankland SJ. Podocyte disorders: Core Curriculum 2011. Am J Kidney Dis. 2011;58(4):666-677.
132. Debiec H, Guigonis V, Mougenot B, etal. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med. 2002;346(26):2053-2060.
133. Beck LH Jr, Bonegio RG, Lambeau G, etal. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11-21.
134. Susani M, Schulze M, Exner M, Kerjaschki D. Antibodies to glycolipids activate complement and promote proteinuria in passive Heymann nephritis. Am J Pathol. 1994;144(4):807-819.
135. Zhang H, Cybulsky AV, Aoudjit L, etal. Role of Rho-GTPases in complement-mediated glomerular epithelial cell injury. Am J Physiol Renal Physiol. 2007;293(1):F148-F156.
136. Nakatsue T, Koike H, Han GD, etal. Nephrin and podocin dissociate at the onset of proteinuria in experimental membranous nephropathy. Kidney Int. 2005;67(6):2239-2253.
137. Saran AM, Yuan H, Takeuchi E, McLaughlin M, Salant DJ. Complement mediates nephrin redistribution and actin dissociation in experimental membranous nephropathy. Kidney Int. 2003;64(6):2072-2078.
138. Hill GS. Hypertensive nephrosclerosis. Curr Opin Nephrol Hypertens. 2008;17(3):266-270.
139. Tracy RE. Age trends of renal arteriolar hyalinization explored with the aid of serial sections. Nephron Clin Pract. 2007;105(4):c171-c177.
140. Camici M, Carpi A, Cini G, Galetta F, Abraham N. Podocyte dysfunction in aging-related glomerulosclerosis. Front Biosci (Schol Ed). 2011;3:995-1006.
141. O'Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. Hypertension. 2005;46(1):200-204.
142. Hill GS, Heudes D, Jacquot C, Gauthier E, Bariety J. Morphometric evidence for impairment of renal autoregulation in advanced essential hypertension. Kidney Int. 2006;69(5):823-831.
143. Fine LG, Orphanides C, Norman JT. Progressive renal disease: the chronic hypoxia hypothesis. Kidney Int Suppl. 1998;65:S74-S78.
144. Freedman BI, Hicks PJ, Bostrom MA, etal. Polymorphisms in the non-muscle myosin heavy chain 9gene (MYH9) are strongly associated with end-stage renal disease historically attributed to hypertension in African Americans. Kidney Int. 2009;75(7):736-745.
145. Freedman BI, Murea M. Target organ damage in African American hypertension: role of APOL1. Curr Hypertens Rep. 2012;14(1):21-28.
146. Arrondel C, Vodovar N, Knebelmann B, etal. Expression of the nonmuscle myosin heavy chain IIA in the human kidney and screening for MYH9mutations in Epstein and Fechtner syndromes. J Am Soc Nephrol. 2002;13(1):65-74.
147. Genovese G, Friedman DJ, Ross MD, etal. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science. 2010;329(5993):841-845.
148. Kao WH, Klag MJ, Meoni LA, etal. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet. 2008;40(10):1185-1192.
149. Tzur S, Rosset S, Shemer R, etal. Missense mutations in the APOL1gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet. 2010;128(3):345-350.
150. Molitch ME, DeFronzo RA, Franz MJ, etal. Nephropathy in diabetes. Diabetes Care. 2004;27 Suppl 1:S79-S83.
151. Tervaert TW, Mooyaart AL, Amann K, etal. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol. 2010;21(4):556-563.
152. Ziyadeh FN, Wolf G. Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Curr Diabetes Rev. 2008;4(1):39-45.
153. Pagtalunan ME, Miller PL, Jumping-Eagle S, etal. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest. 1997;99(2):342-348.
154. White KE, Bilous RW. Structural alterations to the podocyte are related to proteinuria in type 2 diabetic patients. Nephrol Dial Transplant. 2004;19(6):1437-1440.
155. Koop K, Eikmans M, Baelde HJ, etal. Expression of podocyte-associated molecules in acquired human kidney diseases. J Am Soc Nephrol. 2003;14(8):2063-2071.
156. Benigni A, Gagliardini E, Tomasoni S, etal. Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy. Kidney Int. 2004;65(6):2193-2200.
157. Ma H, Togawa A, Soda K, etal. Inhibition of podocyte FAK protects against proteinuria and foot process effacement. J Am Soc Nephrol. 2010;21(7):1145-1156.
158. Dai C, Stolz DB, Bastacky SI, etal. Essential role of integrin-linked kinase in podocyte biology: Bridging the integrin and slit diaphragm signaling. J Am Soc Nephrol. 2006;17(8):2164-2175.
159. El-Aouni C, Herbach N, Blattner SM, etal. Podocyte-specific deletion of integrin-linked kinase results in severe glomerular basement membrane alterations and progressive glomerulosclerosis. J Am Soc Nephrol. 2006;17(5):1334-1344.
160. Hodgin JB, Liang X, Blattner SM, etal. TH-OR028: PINCH-1 and-2 are essential for podocyte adhesion, shape modulation and maintenance of glomerular filtration barrier function. Proceedings of ASN (American Society of Nephrology) Conference; November 8-13, 2011; Philadelphia, PA, USA.
161. Tian X, Zheng R, Zent R, Ishibe S. TH-OR029: Loss of talin 1 in podocytes results in severe progressive albuminuria and kidney failure. Proceedings of ASN (American Society of Nephrology) Conference; November 8-13, 2011; Philadelphia, PA, USA.
162. Kang YS, Li Y, Dai C, Kiss LP, Wu C, Liu Y. Inhibition of integrin-linked kinase blocks podocyte epithelial-mesenchymal transition and ameliorates proteinuria. Kidney Int. 2010;78(4):363-373.
163. Ma H, Togawa A, Soda K, etal. Inhibition of podocyte FAK protects against proteinuria and foot process effacement. J Am Soc Nephrol. 2010;21(7):1145-1156.
164. Garcia-Mata R, Boulter E, Burridge K. The 'invisible hand': regulation of RHO GTPases by RHOGDIs. Nat Rev Mol Cell Biol. 2011;12(8):493-504.
165. Tian J, Wang HP, Mao YY, Jin J, Chen JH. Reduced glomerular epithelial protein 1 expression and podocyte injury in immunoglobulin A nephropathy. J Int Med Res. 2007;35(3):338-345.
166. Cram EJ, Clark SG, Schwarzbauer JE. Talin loss-of-function uncovers roles in cell contractility and migration in C. elegans. J Cell Sci. 2003;116(Pt 19):3871-3878.
167. Lee M, Cram EJ, Shen B, Schwarzbauer JE. Roles for beta(pat-3) integrins in development and function of Caenorhabditis elegans muscles and gonads. J Biol Chem. 2001;276(39):36404-36410.
168. Ono K, Ono S. Tropomyosin and troponin are required for ovarian contraction in the Caenorhabditis elegans reproductive system. Mol Biol Cell. 2004;15(6):2782-2793.
169. Liu S, Lu W, Obara T, etal. A defect in a novel Nek-family kinase causes cystic kidney disease in the mouse and in zebrafish. Development. 2002;129(24):5839-5846.
170. Pelletier J, Bruening W, Kashtan CE et al. Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell. 1991;67(2):437-447.
171. Pelletier J, Schalling M, Buckler AJ, Rogers A, Haber DA, Housman D. Expression of the Wilms' tumor gene WT1 in the murine urogenital system. Genes Dev. 1991;5(8):1345-1356.
172. Morello R, Zhou G, Dreyer SD et al. Regulation of glomerular basement membrane collagen expression by LMX1B contributes to renal disease in nail patella syndrome. Nat Genet. 2001;27(2):205-208.
173. Schnabel E, Anderson JM, Farquhar MG. The tight junction protein ZO-1 is concentrated along slit diaphragms of the glomerular epithelium. J Cell Biol. 1990;111(3):1255-1263.
174. Wharram BL, Goyal M, Gillespie PJ et al. Altered podocyte structure in GLEPP1 (Ptpro)-deficient mice associated with hypertension and low glomerular filtration rate. J CLin Invest. 2000;106(10):1281-1290.
175. Tian J, Wang HP, Mao YY, Jin J, Chen JH. Reduced glomerular epithelial protein 1 expression and podocyte injury in immunoglobulin A nephropathy. J Int Med Res. 2007;35(3):338-345.